Does the Urinary Mast Cell Mediators Predict the Immune Response to BCG in Patients with Primary High-Grade Non-Muscle Invasive Bladder Cancer?
Keywords: BCG; bladder cancer; immunotherapy; mast cell; mediator
Running Title: Mast Cell Mediators in Bladder Cancer
  1. Muhammed Fatih Simsekoglu, Department of Urology, University of Istanbul-Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, Turkey
  2. Islim Kaleler, Department of Biochemistry, University of Istanbul-Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, Turkey
  3. Bulent Onal, Department of Urology, University of Istanbul-Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, Turkey
  4. Cetin Demirdag, Department of Urology, University of Istanbul-Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, Turkey
  5. Sinharib Citgez, Department of Urology, University of Istanbul-Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, Turkey
  6. Ezel Uslu, Department of Biochemistry, University of Istanbul-Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, Turkey
  7. Ahmet Erozenci, Department of Urology, University of Istanbul-Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, Turkey
  8. Zubeyr Talat, Department of Urology, University of Istanbul-Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, Turkey
Conflict of interest : The authors declare that they have no conflict of interest.
Funding source : This study was conducted with the financial support of the Istanbul University-Cerrahpasa Board of Scientific Research Projects (Number: 30651)Ethical approval: This study was approved by the institutional review board of Istanbul University-Cerrahpasa.
Informed consent: Informed consent was obtained from all individual participants included in the study.
Contribution statement: All authors contributed the study.
Data Availability statements: The datasets generated during and/or analyzed during the current study are not publicly available due (Personal Data Protection Law) but are available from the corresponding author on reasonable request.